Dual–mode action of scalable, high–quality engineered stem cell–derived SIRPα–extracellular vesicles for treating acute liver failure
Seohyun Kim,Yoon Kyoung Kim,Seonghyun Kim,Yong-Soon Choi,Inkyu Lee,Hyemin Joo,Jaehyun Kim,Minjeong Kwon,Seryoung Park,Min Kyoung Jo,Yoonjeong Choi,Theresa D'Souza,Jae Woong Jung,Elie Zakhem,Stephen Lenzini,Jiwan Woo,Hongyoon Choi,Jeongbin Park,Seung-Yoon Park,Gi Beom Kim,Gi-Hoon Nam,In-San Kim
DOI: https://doi.org/10.1101/2024.05.24.592430
2024-07-07
Abstract:Acute liver failure (ALF) is a critical inflammatory condition characterized by rapid hepatocyte death, impaired liver regeneration due to the delayed removal of necroptotic cells, and high mortality rates. This study introduces a novel dual-mode action therapeutic approach using extracellular vesicles expressing Signal Regulatory Protein Alpha (SIRP–EVs) derived from genetically engineered mesenchymal stem cells (MSCs). These SIRP–EVs are designed to concurrently resolve necroptosis and promote liver regeneration. Our studies identified CD47 and SIRPα as promising therapeutic targets for ALF. We developed a scalable 3D bioreactor–based process that produces high–purity SIRP–EVs, which preserve MSC properties and achieve significant production levels. SIRP–EVs effectively target and block CD47, a 'don't eat me' signal on necroptotic hepatocytes, while concurrently delivering MSC–derived regenerative proteins to the damaged tissue. Comprehensive and studies demonstrate that SIRP–EVs decrease CD47 necroptotic cells and promote liver regeneration in ALF models, leading to reduced liver damage markers and enhanced survival rates. These findings highlight the potential of SIRP–EVs as a dual–mode action therapeutic for ALF, offering promising prospects for their application in other inflammatory diseases. Moreover, these results pave the way for advancing engineered EV–based therapies toward clinical implementation.
Bioengineering